Intravenous Immunoglobulin: A Drug Utilization Review at Shahid Sadoughi Hospital in Yazd

  • SeyedMojtaba Sohrevardi Associate Professor of Clinical Pharmacy, Department of Pharmaceutics, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
  • Alireza Shafiei Assistant Professor of Asthma, Allergy and Clinical Immunology, Department of Pediatrics, Tehran University of Medical Sciences, Tehran, Iran.
  • ShimaSadat Mirzania Pharmacy Student, Shahid Sadoughi University of Medical Sciences and Health Services, Yazd, Iran.
Keywords: Drug Utilization Review, Intravenous Immunoglobulins, Hospital


 Background: Drug use evaluation (DUE) aims at improving the patients’ care. Studying the administration pattern of intravenous immunoglobulin (IVIG) is an important research topic due to its significant role in the treatment and controlling of many disorders, high prices, and limited availability of this drug.Methods: This observational cross-sectional study was conducted at Shahid Sadoughi Hospital in Yazd, central Iran, from May to September 2014. The orders of different wards in the hospital for IVIG given to the hospital central pharmacy were surveyed. Also, a special form developed for evaluation the method of administration. The related physician and nurse were consulted on drug complications and the causes. Finally, the gleaned data were compared to the available standards on the prescription and administration of IVIG.Results: A total of 75 patients received IVIG during this study. 58.7% of the prescriptions belonged to the cases approved by Food and Drug Administration (FDA). The most frequent cause of the use of IVIG was idiopathic thrombocytopenic purpura (ITP). The rate and dose of administration was suitable in most of the patients, yet, the measurement of laboratory parameters required for IVIG were observed in only a few cases. Complications occurred in 26.7% of the patients receiving it, which was mostly related to infusion-related reactions. On the whole, 3922 g IVIG was used during this study of which 1848 g belonged to the cases approved by FDA.Conclusion: Regarding the high costs of IVIG, complications, and limited information on the quality of the effect of this drug in the treatment of many cases, physicians should be cautious enough with its appropriate use. Besides, the presence of a clinical pharmacist in the health-care team not only improves the quality of drug therapy and treatment results, but also plays an important part in decreasing the treatment costs for the patients.


Looney RJ, Huggins J. Use of Intravenous Immunoglobulin G (IVIG). Best Pract Res Clin Haematol 2006;19(1):3-25.

Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010;125(6): 1354-1360.e4.

American Society of Health-System Pharmacists. ASHP guidelines on medication-use evaluation. Am J Health-Syst Pharm 1996; 53:1953–5.

4. Mohammadi M, Mirrahimi B, Mousavi S, Moradi M. Drug Use Evaluation of Three Widely Prescribed Antibiotics in a Teaching Hospital in East of Iran. J Pharm Care 2013;1(3):100-3.

Dashti-Khavidaki S, Khalili H, Farshadi F,Aghamohammadi A, Movahedi M, Hajibabaei M. Inpatient pediatric use of intravenous immunoglobulin at an academic medical centre. Singapore Med J 2008;49(2):147-9.

Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117(4):S525- 53.

McEvoy GK. AHFS drug information. American Society of Health-System Pharmacists; 2010:3330-43.

Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 2012;367(21):2015-25.

Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion 2006;46(5):741-53.

Di Rosa R, Pietrosanti M, Luzi G, Salemi S, D’Amelio R. Polyclonal intravenous immunoglobulin: an important additional strategy in sepsis. Eur J Intern Med 2014;25(6):511-6.

Yanagimoto K, Nomura Y, Masuda K, et al. Immunoglobulin G values before treatment are correlated with the responsiveness to initial intravenous immunoglobulin therapy for Kawasaki disease. Int Arch Allergy Immunol 2014;164(2):83-8.

Mohammadzadeh I, Tamaddoni A, Atar Zadeh SH, Arzani A. Assessment of IVIG treatment in children and its complications, Babol, 1999-2004. Journal of Babol University of Medical Sciences 2006; 8(30): 32-5.

Ancona KG, Parker RI, Atlas MP, Prakash D. Randomized trial of high-dose methylprednisolone versus intravenous immunoglobulin for the treatment of acute idiopathic thrombocytopenic purpura in children. J Pediatr Hematol Oncol 2002;24(7):540-4.

Hanna K, Poulin-Costello M, Preston M, Maresky N. Intravenous immune globulin use in Canada. Can J Clin Pharmacol 2003;10(1):11-6.

Bjorkander J, Wadsworth C, Hanson LA. 1040 prophylactic infusions with an unmodified intravenous immunoglobulin product causing few side-effects in patients with antibody deficiency syndromes. Infection 1985;13(3):102-10.

Dashti-Khavidaki S, Aghamohammadi A, Farshadi F, et al. Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases. J Investig Allergol Clin Immunol 2009;19(2):139-45.

Kahwaji J, Barker E, Pepkowitz S, et al. Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. Clin J Am Soc Nephrol 2009;4(12):1993-7.

Daw Z, Padmore R, Neurath D, et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis. Transfusion 2008;48(8):1598-601.

Brennan VM, Salome-Bentley NJ, Chapel HM. Prospective audit of adverse reactions occurring in 459 primary antibody-deficient patients receiving intravenous immunoglobulin. Clin Exp Immunol 2003;133(2):247-51.

Winters JL, Brown D, Hazard E, Chainani A, Andrzejewski C Jr. Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barre syndrome. BMC Health Serv Res 2011;11:101.

Leong H, Stachnik J, Bonk ME, Matuszewski KA. Unlabeled uses of intravenous immune globulin. Am J Health Syst Pharm 2008;65(19):1815-24.

Dashti-Khavidaki S, Khalili H, Hamishekar H, Shahverdi S. Clinical pharmacy services in an Iranian teaching hospital: a descriptive study. Pharm World Sci 2009;31(6):696-700.

Sohrevardi SM, Mirjalili MR, Jarrahzadeh MH, Mirjalili M, Mirzaei E. Evaluating the Frequency of Errors in Preparation and Administration of Intravenous Medications in the Intensive Care Unit of Shahid-Sadoughi Hospital in Yazd. J Pharm Care 2014; 2 (3): 114-19.

How to Cite
Sohrevardi S, Shafiei A, Mirzania S. Intravenous Immunoglobulin: A Drug Utilization Review at Shahid Sadoughi Hospital in Yazd. J Pharm Care. 2(4):170-176.
Original Article(s)